High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.

[1]  G. Watts,et al.  Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. , 2016, European heart journal.

[2]  J. Witztum,et al.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study , 2015, The Lancet.

[3]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[4]  N. Seidah,et al.  Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor* , 2015, The Journal of Biological Chemistry.

[5]  R. Giugliano,et al.  Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. , 2014, European heart journal.

[6]  J. Borén,et al.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[7]  J. Ordovás,et al.  Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. , 2014, Journal of the American College of Cardiology.

[8]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[9]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[10]  Sonia Shah,et al.  Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study , 2013, The Lancet.

[11]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[12]  S. Tsimikas,et al.  Emerging therapeutic agents to lower lipoprotein (a) levels , 2012, Current opinion in lipidology.

[13]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  J. Emery,et al.  Familial hypercholesterolaemia: a model of care for Australasia. , 2011, Atherosclerosis. Supplements.

[15]  M. Okubo,et al.  Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[16]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[17]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[18]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[19]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[20]  J. Frohlich,et al.  Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. , 2005, Clinical chemistry.

[21]  B. Nordestgaard,et al.  Phenotype of Heterozygotes for Low-Density Lipoprotein Receptor Mutations Identified in Different Background Populations , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[22]  E. Sijbrands,et al.  The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients , 2004, Journal of internal medicine.

[23]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[24]  F. Kronenberg,et al.  Concentrations of the atherogenic Lp(a) are elevated in FH. , 1998, European journal of human genetics : EJHG.

[25]  D. Rader,et al.  The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. , 1995, The Journal of clinical investigation.

[26]  M. Leppert,et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.

[27]  E. Bruckert,et al.  Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype. , 1991, Atherosclerosis.

[28]  B. Angelin,et al.  Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia , 1990, The Lancet.

[29]  E. Boerwinkle,et al.  Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. , 1990, The New England journal of medicine.